Avenza Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 9.95 Cr
as on 10-12-2024
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 58.64 Cr
as on 10-12-2024
- Revenue %
(FY 2022)
- Ebitda
- Net Worth
- Total Assets 171.07%
(FY 2022)
About Avenza Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.95 Cr.
The company currently has active open charges totaling ₹58.64 Cr.
Dhruvalkumar Patel, Vedant Maheshwari, and Dilavar Abhavani serve as directors at the Company.
- CIN/LLPIN
U24132GJ2015PTC084912
- Company No.
084912
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Oct 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Avenza Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilavar Abhavani  | Director | 28-Oct-2015 | Current |
| Dhruvalkumar Patel | Director | 28-Oct-2015 | Current |
| Vedant Maheshwari | Director | 28-Oct-2015 | Current |
Financial Performance of Avenza Pharmaceuticals.
Avenza Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Avenza Pharmaceuticals?
In 2022, Avenza Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹58.64 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 58.40 Cr
- Indian Bank : 0.24 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 May 2022 | Indian Bank | ₹2.38 M | Open |
| 06 Jan 2021 | Others | ₹29.20 Cr | Open |
| 20 Dec 2020 | Others | ₹29.20 Cr | Open |
How Many Employees Work at Avenza Pharmaceuticals?
Avenza Pharmaceuticals has a workforce of 76 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avenza Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avenza Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.